| control | age | sex | Duration of IOP | VA | logmar | control |
|---------|-----|-----|----------------|----|--------|---------|
| Table1  | 56 M | 19  | 17             | 0.03 | 1.522  | Table2  |
| 2       | 58 M | 16  | 15 movement    | 2.3 |        |         |
| 3       | 65 M | 18  | 14             | 0.03 | 1.522  |         |
| 4       | 55 M | 13  | 13             | 0.02 | 1.7    |         |
| 5       | 56 M | 17  | 17             | 0.03 | 1.522  |         |
| 6       | 61 F | 20  | 16 movement    | 2.3 |        |         |
| 7       | 60 F | 18  | 15             | 0.02 | 1.7    |         |
| 8       | 57 F | 14  | 19             | 0.02 | 1.7    |         |
| 9       | 65 F | 17  | 17             | 0.04 | 1.398  |         |
| 10      | 57 M | 15  | 14 movement    | 1.85|        |         |
| 11      | 56 M | 12  | 16             | 0.02 | 1.7    |         |
| 12      | 64 M | 16  | 19             | 0.02 | 1.7    |         |
| 13      | 62 F | 18  | 16 movement    | 2.3 |        |         |
| 14      | 55 F | 15  | 14             | 0.02 | 1.7    |         |
| 15      | 64 F | 15  | 17             | 0.08 | 1.097  |         |
| 16      | 55 M | 13  | 17             | 0.08 | 1.097  |         |
| 17      | 57 F | 16  | 15             | 0.08 | 1.097  |         |
| 18      | 62 F | 18  | 14             | 0.08 | 1.097  |         |
| 19      | 60 M | 17  | 13 movement    | 2.3 |        |         |
| 20      | 63 F | 19  | 17 movement    | 2.3 |        |         |
| 21      | 64 F | 15  | 16 movement    | 2.3 |        |         |
| 22      | 56 M | 20  | 13 movement    | 2.3 |        |         |
| 23      | 59 F | 17  | 17             | 0.09 | 1.046  |         |
| 24      | 62 F | 16  | 17             | 0.09 | 1.046  |         |
| 25      | 63 M | 15  | 11             | 0.1 | 1      |         |
| 26      | 55 F | 20  | 18             | 0.1 | 1      |         |
| 27      | 61 F | 15  | 16             | 0.1 | 1      |         |
| 28      | 57 M | 13  | 20             | 0.07 | 1.15   |         |
| 29      | 55 F | 15  | 16             | 0.06 | 1.222  |         |
| 30      | 56 M | 16  | 15             | 0.08 | 1.097  |         |
| 31      | 63 F | 17  | 15             | 0.15 | 0.823  |         |
| 32      | 64 M | 20  | 12             | 0.15 | 0.823  |         |

| IVRgroup | age  | sex | Duration of IOP | VA | logmar | IVR |
|----------|------|-----|----------------|----|--------|-----|
| Table1   | 57 M | 13  | 16             | 0.04 | 1.398  |     |
| 2        | 57 F | 13  | 16             | 0.02 | 1.7    |     |
| 3        | 61 F | 20  | 15             | 0.02 | 1.7    |     |
| 4        | 56 M | 11  | 13             | 0.02 | 1.7    |     |
| 5        | 64 F | 16  | 19             | 0.03 | 1.522  |     |
| 6        | 59 M | 16  | 16             | 0.03 | 1.522  |     |
| 7        | 57 M | 13  | 12             | 0.02 | 1.7    |     |
| 8        | 63 F | 20  | 15             | 0.04 | 1.398  |     |
|    | CMT |    |    |    |    |
|---|-----|---|---|---|---|
| 1 | 291 | 250 | 210 |
| 2 | 397 | 267 | 259 |
| 3 | 298 | 321 | 256 |
| 4 | 498 | 345 | 250 |
| 5 | 500 | 278 | 257 |
| 6 | 467 | 290 | 268 |
| 7 | 378 | 286 | 276 |
| 8 | 456 | 300 | 220 |
| 9 | 503 | 367 | 298 |
| 10 | 345 | 358 | 232 |
| 11 | 278 | 356 | 210 |
| 12 | 345 | 389 | 228 |
| 13 | 222 | 400 | 235 |
| 14 | 278 | 367 | 246 |
| 15 | 456 | 410 | 257 |
| 16 | 320 | 269 | 278 |
| 17 | 412 | 250 | 265 |
| 18 | 310 | 389 | 289 |
| 19 | 467 | 290 | 290 |
| 20 | 500 | 400 | 307 |
| 21 | 389 | 327 | 289 |
| control group Duration of vitrectomy | IVR group Duration of vitrectomy |
|-------------------------------------|----------------------------------|
| 1        78                        | 1       75                        |
| 2        90                        | 2       90                        |
| 3        130                       | 3       87                        |
| 4        348                       | 4       90                        |
| 5        150                       | 5       91                        |
| 6        100                       | 6       92                        |
| 7        148                       | 7       89                        |
| 8        134                       | 8       90                        |
| 9        139                       | 9       87                        |
| 10       140                       | 10      100                       |
| 11       137                       | 11      129                       |
| 12       137                       | 12      79                        |
| 13       135                       | 13      90                        |
| 14       126                       | 14      93                        |
| 15       120                       | 15      96                        |
| 16       120                       | 16      93                        |
| 17       132                       | 17      111                       |
| 18       140                       | 18      93                        |
| 19       100                       | 19      87                        |
| 20       120                       | 20      93                        |
| 21       123                       | 21      98                        |
| 22       132                       | 22      92                        |
| 23       149                       | 23      98                        |
| 24       145                       | 24      90                        |
| 25       128                       | 25      100                       |
| 26       124                       | 26      87                        |
| 27       127                       | 27      90                        |
| 28       135                       | 28      98                        |
| 29       140                       | 29      85                        |
| 30       125                       | 30      87                        |
| 31       156                       | 31      80                        |
| 32       125                       |                        |
| Procedure                      | Control Group | IVR Group |
|-------------------------------|---------------|-----------|
| Intraoperative bleeding       | 12 (37.50%)   | 4 (12.90%)|
| Iatrogenic retinal break     | 21 (65.625%)   | 3 (9.68%) |
| Endodiathermy application    | 12 (37.50%)   | 2 (6.45%) |
| SO tamponade                  | 13 (40.625%)  | 4 (12.90%)|

**Table 3  Visual Acuity Improvement**

| BCVA    | Control Group | IVR Group |
|---------|---------------|-----------|
| Improvement | 9 (28.125%)   | 21 (67.74%)|
| No change  | 21 (65.625%)   | 10 (32.26%)|
| Decrease  | 2 (6.25%)      | 0 (0.00%) |
| post1mo | logmar | post3mon | logmar | post6mon | logmar |
|---------|--------|----------|--------|----------|--------|
| 0.04    | 1.398  | 0.2      | 0.699  | 0.5      | 0.301  |
| 0.04    | 1.398  | 0.2      | 0.699  | 0.4      | 0.398  |
| 0.09    | 1.406  | 0.2      | 0.699  | 0.5      | 0.301  |
| 0.15    | 0.823  | 0.2      | 0.699  | 0.25     | 0.602  |
| 0.06    | 1.222  | 0.25     | 0.602  | 0.4      | 0.398  |
| 0.04    | 1.398  | 0.25     | 0.602  | 0.25     | 0.602  |
| 0.05    | 1.301  | 0.25     | 0.602  | 0.5      | 0.301  |

**Movement**

| movement | 2.3 | 0.25 | 0.602 | 0.4 | 0.398 |
|----------|-----|------|-------|-----|-------|
| 0.04 | 1.398 | 0.25 | 0.602 | 0.4 | 0.398 |
| 0.05 | 1.301 | 0.25 | 0.602 | 0.5 | 0.301 |

**Counting Fingers**

| counting | 1.85 | 0.3 | 0.523 | 0.4 | 0.398 |
|----------|-----|----|------|-----|-------|
| 0.04 | 1.398 | 0.25 | 0.602 | 0.4 | 0.398 |
| 0.02 | 1.7 | 0.3 | 0.523 | 0.6 | 0.222 |
| 0.02 | 1.7 | 0.3 | 0.523 | 0.4 | 0.398 |
| 0.05 | 1.301 | 0.2 | 0.699 | 0.25 | 0.602 |
| 0.07 | 1.155 | 0.2 | 0.699 | 0.5 | 0.301 |
| 0.01 | 1 | 0.2 | 0.699 | 0.3 | 0.523 |
| 0.04 | 1.398 | 0.25 | 0.602 | 0.4 | 0.398 |
| 0.06 | 1.222 | 0.25 | 0.602 | 0.4 | 0.398 |
| 0.09 | 1.046 | 0.25 | 0.602 | 0.3 | 0.398 |
| 0.01 | 1 | 0.25 | 0.602 | 0.4 | 0.398 |
| 0.06 | 1.222 | 0.3 | 0.523 | 0.4 | 0.398 |
| 0.02 | 1.7 | 0.3 | 0.523 | 0.3 | 0.523 |
| 0.03 | 1.522 | 0.3 | 0.523 | 0.4 | 0.398 |
| 0.1 | 1 | 0.3 | 0.523 | 0.4 | 0.398 |
| 0.04 | 1.398 | 0.3 | 0.523 | 0.4 | 0.398 |
| 0.02 | 1.7 | 0.3 | 0.523 | 0.4 | 0.398 |

| post1 mon | logmar | post 3 mon | logmar | post 6 mon | logmar |
|-----------|--------|------------|--------|------------|--------|
| 0.25      | 0.602  | 0.4        | 0.398  | 0.2        | 0.699  |
| 0.2       | 0.699  | 0.5        | 0.301  | 0.25       | 0.602  |
| 0.25      | 0.602  | 0.3        | 0.523  | 0.3        | 0.523  |
| 0.2       | 0.699  | 0.4        | 0.398  | 0.3        | 0.523  |
| 0.3       | 0.523  | 0.4        | 0.398  | 0.3        | 0.523  |
| 0.3       | 0.523  | 0.2        | 0.699  | 0.4        | 0.398  |
| 0.2       | 0.699  | 0.25       | 0.602  | 0.4        | 0.398  |
| 0.2       | 0.699  | 0.3        | 0.523  | 0.4        | 0.398  |
| IVRgroup | post 1 mon | post 3 mon | post 6 mon |
|----------|-----------|------------|------------|
| 1        | 220       | 200        | 200        |
| 2        | 236       | 345        | 213        |
| 3        | 245       | 245        | 210        |
| 4        | 255       | 234        | 234        |
| 5        | 267       | 234        | 256        |
| 6        | 245       | 200        | 300        |
| 7        | 300       | 245        | 305        |
| 8        | 369       | 267        | 267        |
| 9        | 370       | 300        | 256        |
| 10       | 377       | 312        | 267        |
| 11       | 345       | 267        | 278        |
| 12       | 312       | 278        | 299        |
| 13       | 234       | 289        | 300        |
| 14       | 345       | 300        | 210        |
| 15       | 235       | 215        | 220        |
| 16       | 261       | 267        | 234        |
| 17       | 256       | 278        | 256        |
| 18       | 367       | 288        | 236        |
| 19       | 345       | 290        | 245        |
| 20       | 235       | 267        | 267        |
| 21       | 234       | 289        | 234        |
|   | control group | IVR group |
|---|---------------|-----------|
| 22| 278           | 290       | 256       |
| 23| 300           | 300       | 245       |
| 24| 345           | 245       | 234       |
| 25| 345           | 250       | 278       |
| 26| 256           | 256       | 280       |
| 27| 323           | 245       | 290       |
| 28| 312           | 267       | 300       |
| 29| 256           | 256       | 234       |
| 30| 278           | 245       | 245       |
| 31| 234           | 289       | 278       |

**Table 1**: Vitreous hemorrhage score
| Grade of ME | Modern  | Sever  |
|------------|---------|--------|
| Mild       | 3 (9.375%) | 2 (6.45%) |
| Modern     | 15 (46.875%) | 16 (51.61%) |
| Sever      | 14 (43.7%)  | 13 (41.94%) |
### Table 1

|       | age          | Duration of diabetes | logmar   | IOP         |
|-------|--------------|----------------------|----------|-------------|
| Control | 59.47±3.56   | 16.16±2.40           | 1.52±0.51| 15.69±2.09 |
| IVR    | 58.87±3.02   | 16.48±2.19           | 1.56±0.62| 16.65±2.50 |
| t      | 0.72         | -0.57                | -0.31    | -1.66       |
| P      | (0.48)       | (0.57)               | 0.76     | 0.10        |

Sex: $\chi^2=0.014$, P > 0.05 (0.904)

Vitreous hemorrhage score: $\chi^2=0.14$, P > 0.05 (0.71)

Grade of ME: $\chi^2=0.253$, P > 0.05 (0.881)

### Table 2

|                  | pro vs post1mon | pro vs post 3 mon | pro vs post 6 mon |
|------------------|-----------------|-------------------|-------------------|
| control:         |                 |                   |                   |
| pro vs post1mon  | 1.52±0.51 vs 1.43±0.41 | t=0.74            | >0.05 (0.46)      |
| pro vs post 3 mon| 1.52±0.51 vs 0.58±0.07  | t=10.34           | <0.01 (0.000)    |
| pro vs post 6 mon| 1.52±0.51 vs 0.41±0.10  | t=12.14           | <0.01 (0.000)    |
| IVR:             |                 |                   |                   |
| pro vs post1mon  | 1.56±0.62 vs 0.59±0.11  | t=8.59            | <0.01             |
| pro vs post 3 mon| 1.56±0.62 vs 0.40±0.11  | t=10.30           | <0.01             |
| pro vs post 6 mon| 1.56±0.62 vs 0.38±0.13  | t=10.47           | <0.01             |

control and IVR

|            | LogMAR          |        |        |        |
|------------|-----------------|--------|--------|--------|
|            | pro             | post 1mon | post3mon | post6mon |
| Control    | 1.52±0.51       | 1.43±0.41 | 0.58±0.07 | 0.41±0.10 |
| IVR        | 1.56±0.62       | 0.59±0.11 | 0.40±0.11 | 0.37±0.13 |
| t          | -0.306          | 10.94   | 7.93   | 1.32   |
| P          | >0.05           | <0.001  | <0.001 | >0.05  |

Table 3
$\chi^2 = 10.69, \ P < 0.01 \ (0.005)$

table 4  CMT

|       | CMT            | post 1mon | post3mon | post6mon |
|-------|----------------|-----------|-----------|-----------|
| Control | 380.84 ± 75.65 | 335.06 ± 53.57 | 260.50 ± 27.81 |
| IVR    | 289.68 ± 50.73 | 266.23 ± 32.33 | 255.71 ± 30.17 |
| t      | 5.60           | 6.15       | 0.66      |
| P      | <0.01          | <0.01      | >0.05     |

Table 5

Duration of vitrectomy

control: 135.41 ± 42.39
IVR: 92.6 ± 9.65  t = 5.53  <0.01

Intraoperative bleeding: $\chi^2 = 5.028$,  P < 0.05 (0.025)

Iatrogenic retinal breaks: $\chi^2 = 20.9$,  P < 0.001 (0.000)
Endodiathermy applications: $\chi^2 = 8.78$,  <0.01 (0.003)
Silicone oil tamponade: $\chi^2 = 6.14$,  P < 0.05 (0.013)